A network meta-analysis of safety and efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure patients

Empagliflozin was associated with the lowest risk of both cardiovascular mortality and serious side effects. While all SGLT2 inhibitors reduced the likelihood of hospitalizations for HF, canagliflozin did not show a significant benefit in this area. There were no significant differences between the SGLT2 inhibitors in terms of all-cause mortality, MI, stroke, or side effects leading to treatment discontinuation.